Ekspresi Hypoxia-Inducible Factor-1α menginduksi Ekspresi Eritropoietin Intraseluler, dan Vascular Endothelial Growth Factor pada Penderita Kanker Payudara dengan Anemia

Authors

  • Muhammad Darwin P Laboratorium Ilmu Penyakit Dalam Rumah Sakit Umum Daerah Ulin/Fakultas Kedokteran Unversitas Lambung Mangkurat Banjarmasin
  • Handono Kalim Laboratorium Ilmu Penyakit Dalam Fakultas Kedokteran Universitas Brawijaya Malang
  • Djoko Wahono S Laboratorium Ilmu Penyakit Dalam Fakultas Kedokteran Universitas Brawijaya Malang
  • Aru W Sudoyo Laboratorium Ilmu Penyakit Dalam Fakultas Kedokteran Universitas Indonesia Jakarta
  • Fatchiyah Fatchiyah Jurusan Biologi Fakultas MIPA Universitas Brawijaya Malang

DOI:

https://doi.org/10.21776/ub.jkb.2012.027.02.5

Abstract

 

Anemia merupakan faktor prognostik independen untuk pertahanan hidup pasien kanker. Penurunan kapasitas oksigen pada darah dapat menyebabkan terjadinya kondisi hipoksia pada jaringan kanker . Hipoksia pada jaringan kanker dapat mengaktivasi faktor transkripsi hypoxia-inducible factor-1α (HIF-1α) yang kemudian akan mentranskripsi banyak gen lain yang terlibat dalam invasi sel, angiogenesis, metabolisme anaerobik dan siklus sel, seperti gen eritropoietin (Epo) dan vascular endothelial growth  factor  (VEGF). Penelitian  ini menggunakan sampel berupa 120 slide peraparat  jaringan kanker payudara (60 anemi dan 60 non anemi) dengan melakukan pewarnaan secara  imunofluoresen double staining untuk protein HIF1α dengan VEGF dan Epo dengan EpoR. Sampel dibagi menjadi 2 kelompok, yaitu anemi (Hb 5,5-10,7) dan non anemi (Hb 11-14,9). Hasil imunofluoresen di analisis dengan menggunakan Confocal Laser Scanning Microscope untuk mengetahui ekspresi protein target. Hasil dari penelitian menunjukkan bahwa tidak ada perbedaan yang signifikan pada ekspresi   HIF1α pada jaringan kanker penderita kanker payudara yang   anemi dan   non anemi namun sebaliknya ada perbedaan ekspresi VEGF yang signifikan (p=0,013) antara pasien anemi (754,4±316) dan non anemi (555,1±276,9). Pada kelompok sampel anemi dan non anemi ada hubungan negatif antara Hb dan HIF1α   (p=0,000; r=-0,522) dan hubungan positif  antara HIF1α dengan EPO (p=0,000; r= 0,697), antara HIF1α dengan VEGF (p=0,000; r=0,644), antara Epo dan VEGF (p=0,001; r=0,433). Pada pasien kanker anemi dan non anemi telah terjadi kondisi hipoksia pada lingkungan tumornya sehingga menyebabkan ekspresi HIF1α tidak berbeda signifikan namun hubungan HIF1α dengan EPO dan VEGF sangat kuat.  Kata Kunci: Anemi, epo, HIF1α, hipoksia, VEGF

Downloads

Download data is not yet available.

References

McPherson K, Steel CM, and Dixon JM. Breast Cancer -Epidemiology, Risk Factors, and Genetics. British Medical Journal. 2000; 321(7261): 624-628.

Ferlay J, Shin HR, Bray F, Forman D, Mathers C, and Parkin DM. Estimates of Worldwide Burden of Cancer

in 2008: GLOBOCAN 2008. International Journal of Cancer . 2010; 127(12): 2893-2917.

Harper P and Littlewood T. Anaemia of Cancer: Impact on Patient Fatigue and Long-Term Outcome. Oncology. 2005; 69(2): 2-7.

Overgaard J, Hoff C, Sand Hansen H, et al. Randomized

Study of Novel Erythropoiesis Stimulating Protein (Aranesp®) for the Effect of Radiotherapy in Patients

with Primary Squamous Cell Carcinoma of the Head and Neck (HNSCC)-the Danish Head and Neck Cancer Group DAHANCA 10. European Journal of Cancer . 2007; 5(6): 7.

Graeber TG, Peterson JF, Tsai M, Monica K, Fornace AJ

Jr, and Giaccia AJ. Hypoxia Induces Accumulation of P53 Protein, but Activation of a G1-Phase Checkpoint by Lowoxygen Conditions is Independent of P53 Status. Molecular and Cellular Biology. 1994; 14(9): 6264–6277.

Semenza GL. Targeting HIF-1 for Cancer Therapy. Nature Reviews Cancer . 2003; 3(10): 721-732.

Wang GL and Semenza GL. General Involvement of Hypoxia Inducible Factor 1 in Transcriptional Resresponse to Hypoxia. Proceedings of the National Academy of Sciences of the United States of America. 1993; 90(9): 4304-4308.

Cao D, Hou M, Guan YS, Jiang M, Yang Y , and Gou HF. Expression of HIF-1 Alpha and VEGF in Colorectal Cancer: Association with Clinical Outcomes and Prognostic Implications. BMC Cancer . 2009; 9: 432.

Goncharuk IV, Vorobjova LI, Lukyanova NY , and Chekhun VF. Vascular Endothelial Growth Factor Expression in Uterine Cervical Cancer: Correlation with Clinicopathologic Characteristics and Survival. Experimental Oncology. 2009; 31(3): 179-181.

Lee WR, Berkey B, Marcial V, et al. Anemia is Associated with Decreased Survival and Increased Locoregional Failure in Patients with Locally Advanced Head and Neck Carcinoma: A Secondary Analysis of RTOG 85–27. International Journal of Radiation Oncology *Biology* Physics. 1998; 42(5): 1069–1075.

Hurter B and Bush NJ. Cancer-Related Anemia: Clinical Review and Management Update. Clinical Journal of Oncology Nursing. 2007; 11(3): 349-459.

Glaspy J. Anemia and Fatigue in Cancer Patients.

Cancer . 2001; 92(6): 1719-1724.13. Charles C, George D, Glaspy J, et al. Identifying Hemoglobin Levels for Optimal Quality of Life: Results of an Incremental Analysis. American Society of Clinical Oncology. 1999; 18: 574(a).

Vaupel P and Mayer A. Hypoxia in Cancer: Significance and Impact on Clinical Outcome. Cancer Metastasis Reviews. 2007; 26(2): 225-39.

Brahimi-Horn, Mazure N, and Pouyssegur J. Signalling Via the Hypoxia-Inducible Factor-1alpha Requires Multiple Posttranslational Modifications. Cellular Signalling. 2005; 17(1): 1-9.

Srinivas V, Zhang LP, Zhu XH, and Caro J. Characterization of an Oxygen/Redox-Dependent Degradation Domain of Hypoxia-Inducible Factor Alpha (HIF-Alpha) Proteins. Biochemical and Biophysical Research Communications. 1999; 260(2): 557-561.

Fukuda R, Hirota K, Fan F, Jung YD, Ellis LM, and Semenza GL. Insulin-Like Growth Factor 1 Induces

Hypoxia-Inducible Factor 1-Mediated Vascular Endothelial Growth Factor Expression, which is Dependent on MAP Kinase and Phosphatidylinositol 3-Kinase Signaling in Colon Cancer Cells. The Journal of Biological Chemistry. 2002; 277(41): 38205–38211.

Lahiri S, Semenza GL, and Prabhakar NR. Oxygen Sensing: Responses and Adaptation to Hypoxia. New York: Marcel Dekker Inc.; 2003; p. 95-108.

Dor Y , Porat R, and Keshet E. Vascular Endothelial Growth Factor and Vascular Adjustments to Pertubations in Oxygen Homeostasis. American Journal of Physiology-Cell Physiology. 2001; 280(6): C1367-1374.

Maxwell PH, Dachs GU, Gleadle JM, et al. Hypoxia-Inducible Factor-1 Modulates Gene Expression in Solid Tumors and Influences Both Angiogenesis and Tumor Growth. Proceedings of the National Academy of Sciences of the United States of America. 1997; 94: 8104–8109.

Yoshimura H, Dhar DK, Kohno H, et al. Prognostic Impact of Hypoxia-Inducible Factors 1alpha and 2alpha in Colorectal Cancer Patients: Correlation with Tumor Angiogenesis and Cyclooxygenase-2 Expression. Clinical Cancer Research. 2004; 10(24):

–8560.

Schindl M, Schoppmann SF, Samonigg H, et al. Overexpression of Hypoxia-Inducible Factor 1alpha is Associated with an Unfavorable Prognosis in Lymph Node-Positive Breast Cancer. Clinical Cancer Research. 2002; 8(6): 1831–1837.

Forsythe JA, Jiang BH, Iyer NV, et al. Activation of Vascular Endothel ial Growth Factor Gene Transcription by Hypoxia-Inducible Factor 1. Molecular and Cellular Biology. 1996;16(9): 4604-4613.

Semenza GL. Hypoxia and Cancer. Cancer Metastasis Reviews. 2007; 26: 223-224. 25. Kuwai T, Kitadai Y , Tanaka S, et al. Ekspression of Hypoxia-Inducible Factor-1α is Associated with Tumor Vascularization in Human Colorectal Carcinoma. International Journal of Cancer . 2003; 105(2): 176-181.

Semenza G. Signal Transduction to Hypoxia-Inducible Factor 1. Biochemical Pharmacology. 2002; 64(5-6): 993-998.

Laugsch M, Metzen E, Svensson T, Depping R, and Jelkmann W. Lack of Functional Erythropoietin Receptors of Cancer Cell Lines. International Journal of Cancer . 008; 122(5): 1005–1011.

Acs G, Acs P, Beckwith SM, et al. Erythropoietin and Erythropoietin Receptor Expression in Human Cancer. Cancer Research. 2001; 61(9): 3561-5.

Batra S, Perelman N, Luck LR, Shimada H, and Malik P. Pediatric Tumor Cells Express Erythropoietin and a Functional Erythropoietin Receptor that Promotes Angiogenesis and Tumour Cell Survival. Laboratory Investigation. 2003; 83: 1477–1487.

Downloads

Published

2013-02-11

Issue

Vol. 27 No. 2 (2012)

Section

Research Article

License

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).

Most read articles by the same author(s)